

SAFETY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTICS

MARY ELLEN COSENZA

Amgen Inc., Thousand Oaks, California

Contents

- 1 Introduction
 - 2 Species Specificity and Selection
 - 2.1 Species Selection
 - 2.2 Nonhuman Primates
 - 2.3 Surrogates and Other Alternatives
 - 3 Immunogenicity
 - 3.1 Types of Antibodies to Biotechnology-Derived Pharmaceuticals
 - 3.2 Study Design Issues
 - 4 Special Studies
 - 4.1 Genotoxicity
 - 4.2 Reproductive Toxicology
 - 4.3 Carcinogenicity
 - 4.4 Safety Pharmacology
 - 4.5 Local Tolerance
 - 5 Future Trends
- References

1 INTRODUCTION

Over the course of the last 20 years, the biotechnology field has grown and is now a large part of pharmaceutical therapeutics development. According to a 2006 report from the Pharmaceutical Research and Manufacturers of America (PhRMA)

Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing
Edited by Shayne C. Gad
Copyright © 2010 John Wiley & Sons, Inc.